Summary Long term follow-up of 378 children with acute lymphoblastic leukaemia (ALL) treated at a single centre showed that at six years from diagnosis 202 (53%) were alive, of whom 140 (37%) remained in first remission. Only three children had a first relapse after six years. Children who survived six years despite a single extramedullary relapse in the testis or CNS were likely to remain in second remission but patients with previous marrow or with multiple relapses continued at risk for up to ten years from diagnosis. Presenting factors influencing event-free survival were: leucocyte count, age and sex. After allowing for these factors morphological (FAB) subtype and liver enlargement retained their prognostic significance. Immunological type of ALL was not of independent prognostic significance, except for the small number of patients with B-ALL. Most factors lost their significance after 2-4 years.
The definition of long survival in childhood lymphoblastic leukaemia (ALL) is an arbitrary one. Earlier reports of long survival have followed the fate of patients alive four years from diagnosis (Till et al., 1973; Hardisty et al., 1981) with emphasis on the importance of relapse-free survival and many trials of treatment are reported after about this duration of follow up. Since the introduction of 'modem' therapy most children with ALL have been treated for two or three years, and while most relapses occur either during treatment or within a year of stopping it, later relapses may occur (George et al., 1979) . We have therefore examined the outcome in all children referred to the Hospital for Sick Children since the introduction of modern therapy, who have been followed up for a minimum period of at least six years, in order to ascertain the risk and pattern of later relapses. We have also examined the outcome in children who were alive six years from diagnosis after one or more relapses, to determine which types of patient in this category had a chance of long term survival.
Patients and methods
The patients comprise all children referred to the Hospital for Sick Children for treatment of ALL between 1970 and 1979. All were treated on protocols devised or being piloted for the Medical Research Council (MRC) Working Party on Childhood Leukaemia which have been described in detail elsewhere; (Chessells et al., 1981) . All patients received induction therapy with prednisolone, vincristine and at least one other drug and continuing multiple agent chemotherapy. Measures to prevent the development of overt leukaemic inflitration of the central nervous system (CNS prophylaxis) were used in all patients except those in UKALL I, (i.e. those referred in 1970 and 1971) and comprised cranial irradiation together with a course of intrathecal methotrexate injections and/or spinal irradiation. Many patients were involved in trials of optimal duration of chemotherapy, reported elsewhere (MRC, 1982) , the longest duration being three years. Thus, at the time of analysis, all patients still in their first remission had been off treatment for at least three years.
Patients who had had a bone marrow relapse had received a variety of treatments, many of which have been described elsewhere (Chessells & Cornbleet, 1979; Chessells et al., 1984) . Management of extramedullary relapse evolved over the period under review. Patients in the MRC UKALL I (MRC 1973) trial did not receive CNS prophylaxis and a large number developed CNS relapse, many of whom were entered into the second MRC meningeal trial (Willoughby, 1976) which involved treatment of meningeal relapse with intrathecal methotrexate and a subsequent randomised comparison of cranial and craniospinal irradiation; patients relapsing -l ater all received craniospinal irradiation as previously described (Gribbin et al., 1977) . The management of children relapsing despite CNS prophylaxis evolved to a standard policy of intrathecal chemotherapy, further systemic intensification and further, craniospinal, irradiation (Pinkerton & Chessells, 1984) . Similarly the first few patients with localized testicular relapses did not receive standard chemotheraphy and radiotherapy, but subsequently all patients were treated with bilateral testicular irradiation, systemic reinduction and intensification, intrathecal chemotherapy, and two years of further chemotherapy (Tiedemann et al., 1982) . All the patients have been followed up for a minimum of 6 years from diagnosis and no patients have been lost to follow-up.
Morphological and immunological analyses Morphological (FAB) classification of the leukaemia as originally described by Bennett et al. (1976) , had been carried out at diagnosis on the majority of patients. The leukaemias had been classified immunologically by techniques then available (Greaves et al., 1981) into c-ALL, T-ALL, B-ALL and null-ALL Statistical analyses All statistical analyses were performed by the log-rank method (Peto et al., 1977) . After ascertainment of prognostic variables by unstratified analysis, results were stratified by the most important variables, leucocyte count and age, to determine which were of independent prognostic significance. In order to determine the duration of influence of prognostic variables, analyses were done for each of the periods, up to two years, two to four years and four to six years from diagnosis.
Results
Long term disease-free survival after four and six years Three hundred and seventy-eight children with ALL were treated between 1970 and 1979 of whom 151 (40%) were alive in first remission at four years. Since previous analyses had examined the outcome for patients from four years, we looked first at follow up of all patients in remission at four years and survival is shown for these 151 patients in Figure  1 . It can be seen that the majority of relapses occurred in the fifth and sixth year from diagnosis. Thus, at six years, our time of minimum follow-up, 140 (37%) of all children and 93% of those in remission at four years, remained in remission; two relapses occurred in the seventh year (fourth year off treatment) and one in the eighth year. In all the cases of late relapse the morphological and cytochemical appearance of the leukaemic blast cells was consistent with ALL and, where immunological characterization had been performed, there was no evidence of alteration in phenotype; there was thus no reason to suppose that these relapses represented a new leukaemia. The 137 patients alive in first remission remain in general well and a detailed analysis of their health is in preparation. No second neoplasms have been observed among these sixyear disease-free survivors, although in the whole group of 378 children there have been three. One child developed acute myeloid leukaemia two years from diagnosis and two children developed second neoplasms after bone marrow relapse, one Hodgkin's disease and one a cerebral astrocytoma. All three patients died within 6 years from diagnosis.
Survival after relapse At six years from diagnosis there were 202 children alive of whom 62 had survived after one or more relapses. Twentyone of these patients had relapsed on more than one occasion before six years, and, as shown in Figure 2 , they continued thereafter at risk of further recurrence. Forty-one children had survived to six years from diagnosis having had a single relapse; Table I shows that these survivors comprise a minority of all those relapsing. Only 22 of the 134 children relapsing in the bone marrow, with or without concurrent relapse in the CNS or testis were alive and in second remission at six years and the risk of further relapse, as Figure 2 Follow up of patients who were alive at 6 years after one or more relapses. The curves indicate time to next relapse or death. There are two patients with combined marrow and CNS relapse included in the BM curve. The curve for multiple relapses indicates patients who had survived for 6 years having had more than one relapse. shown in Figure 2 continued after this time. Only 6 of the 49 patients experiencing CNS relapse as a first event survived in next remission to six years. that the majority of those associated with leukaemic cell mass, e.g. leucocyte count, and enlargement of liver and spleen, exert their influence maximally in the first two years and have no influence after 2-4 years, although leucocyte count appears of marginal significance at 4-6 years.
Similarly, age, cell phenotype and FAB subclass are not significant after 2 years. By contrast the effect of sex is only apparent at 2-4 years from diagnosis. Thus, with the exception of sex, most recognized adverse prognostic factors in this series had lost their significance by two, or at most four, years from diagnosis and did not influence the chance of long-term survival beyond that time.
Discussion
At a minimum of six years from diagnosis 53% of the children were alive, one third of survivors having experienced at least one relapse. The importance of maintenance of initial remission is emphasized by the facts that 90% of the children who were alive in remission at four years have continued to survive relapse-free. Only three relapses have occurred so far beyond six years, two of these in the seventh year. It is perhaps significant that two of these three very late relapses occurred in a group of children receiving intermittent maintenance chemotherapy in a pilot protocol for the national MRC UKALL V trial (Rapson et al., 1980) and that a number of late relapses have subsequently been observed in this trial (MRC 1986 ). While our study has the advantage of complete follow-up and the inclusion of all patients seen at a single centre, it does suffer from the disadvantage that the patients received a variety of treatments and that the likelihood of late relapse may vary according to therapeutic schedule. Nevertheless these results are remarkably similar to those originally reported from St Jude Children's Research Hospital (George et al., 1979) when with a minimum follow-up of three years, and all patients treated for two and a half years, the authors observed few relapses in patients more than four years off therapy; a recent follow-up from the same centre estimates that the relapse rate is less than 2% in patients off therapy for more than three years (Rivera & Simone, 1985) . In a multi-institutional study of duration of therapy, the American Children's Cancer Study Group (CCSG) found that no patient surviving more than three years off therapy had subsequently relapsed (Nesbit et al., 1983 (Rivera & Simone, 1985) , but no mention is made of long term outcome in their group. Our results suggest that, as we have previously reported, boys with isolated testicular relapse may achieve long term remissions and even cure (Tiedemann et al., 1982) . We have previously shown that patients who develop overt CNS relapse, with or without previous prophylaxis, are at high risk of subsequent marrow relapse, (Pinkerton & Chessells, 1984) but the present results suggest that if marrow remission is maintained for six years from diagnosis without further recurrence of CNS disease, long term remission and perhaps cure, is possible for some patients.
The results in patients surviving after bone marrow relapse or multiple relapses are in contrast to these findings and confirm our previous reports (Chessells & Cornbleet, 1979; Chessells et al., 1984) . Whether this picture will be improved by the use of more intensive rescue therapy such as chemoradiotherapy and bone marrow transplantation remains to be seen, but seems unlikely from our recent experience (Chessells et al., 1986) .
The dominant prognostic factors influencing the chance of long term remission are, as in most studies, the extent of the disease at presentation as reflected in the height of the leucocyte count and the enlargement of organs, and the age of the patient. The FAB (morphological) subclass of ALL was assigned to the patients without the use of the more recent scoring system (Bennett et al., 1981) but even so it retained, as in other reported series (Hann et al., 1979; Miller et al., 1981) , a strong prognostic significance. The prognostic significance of the immunological subclass of ALL had previously been unclear: we originally reported that immunological subclass was of prognostic significance but in an analysis of MRC data (Greaves et al., 1981) it appeared that the adverse effect of T-ALL was due solely to its association with a high leucocyte count. Follow-up at the time of the latter report was short, and in the present study with long-term follow-up it seems confirmed that apart from the well known poor prognosis of B-ALL, once allowance is made for leucocyte count, the outcome for patients with T-ALL is no worse than that of those with c-or nul-ALL. At the time of our study patients with c-ALL were not further classified by pre-B subtype, so we are unable to confirm or disprove recent reports that patients with pre-B-ALL have a relatively poor prognosis (Crist et al., 1984) . These presenting features are of prognostic significance for the first two, or at the most, four years, but lose their significance thereafter. This disappearance of predictive value was noted by the CCSG in a study with maximum follow-up to five years. The influence of sex on prognosis however is maximal at two to four years, a period approximating to the first year off therapy, but no longer significant at six years.
This report indicates that thirty to forty percent of an unselected group of all children with ALL presenting to a single centre during this ten-year period have been cured. It is difficult to compare these cure rates in all patients treated at a single centre with results reported from multicentre trials, both because of unknown selection in entry of patients to trials and the regrettable tendency for early publication of results. These results seem similar to those reported on long term follow up of patients treated during this period at St Jude Children's Hospital (Rivera & Simone, 1985) but inferior to multi-institutional studies such as those of the CCSG (Miller et al., 1980) and the West German BFM group (Riehm et al., 1983) . Our results confirm that the factors determining prognosis were the long recognized ones of leukaemic mass and age, and also the immunological and morphological subtype of ALL. The child who survives the first two years despite adverse prognostic factors, has however as good a chance of cure. It is to be hoped that the more intensive therapy now given, by preventing relapse in the first two years, will increase the chance of long term remission for the child with ALL.
